OVID
Ovid Therapeutics Inc.
| Exchange: | NASDAQ |
| Market Cap: | 419.89M |
| Shares Outstanding: | 58.451M |
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | BiotechnologyView industry performance | |||||
| CEO: | Margaret Alexander | |||||
| Full Time Employees: | 23 | |||||
| Address: |
| |||||
| Website: | https://www.ovidrx.com |
Click to read more…
Revenue Segmentation
OVID full analysis
Hey everyone, welcome back to MarketSnap. Everyone loves the story behind Ovid Therapeutics. Biotechnology sounds like the future, and it is incredibly easy to buy into the dream of a tiny company curing neurological disorders. But Wall Street doesn't reward dreams — it rewards cash flow. In this video, we aren't looking at the marketing presentations. We are stripping down Ovid's latest financial statements and examining the cold, hard reality of their balance sheet. Is this a generational ground-floor opportunity,…
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| OVID | Ovid Therapeutics Inc. | 419.9M | — | — | -26.1% |
 YDES | YD Bio Limited Ordinary Shares | 419.3M | — | — | -43.4% |
 AGMB | AgomAb Therapeutics N.V. American Depo… | 416.6M | — | — | -11.8% |
 AUTL | Autolus Therapeutics plc | 425.9M | — | — | -57.5% |
 ALT | Altimmune, Inc. | 427.9M | — | — | -19.5% |
 PRTA | Prothena Corporation plc | 428.7M | — | 69.6 | -21.4% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
No earnings call materials on file for this symbol yet.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 392 | 566 | 7,252 |
| Gross Profit | 392 | 566 | 6,952 |
| EBITDA | -57,013 | -57,772 | -17,141 |
| Operating Income | -59,281 | -61,885 | -42,439 |
| Net Income | -52,339 | -26,433 | -17,414 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 144,027 | 92,167 | 150,934 |
| Total Liabilities | 56,230 | 23,941 | 20,274 |
| Total Stockholders Equity | 87,797 | 68,226 | 130,660 |
| Total Debt | 16,002 | 14,755 | 13,419 |
| Cash and Cash Equivalents | 27,042 | 26,301 | 13,153 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -45,780.925 | -55,956 | -38,334 |
| Capital Expenditure | -137.455 | -71 | 0 |
| Free Cash Flow | -45,918.380 | -56,027 | -38,334 |
| Net Income | -52,338.959 | -26,433 | -17,414 |
| Net Change in Cash | -17,826.329 | -740 | -13,148 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 43,773.630 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 116,349.574 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 59,931.250 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | -20,589.023 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | -2,531.910 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | -6,551.976 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | -25,507.358 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | -7,450.245 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | -11,470.311 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 1,277,605.158 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 3,395,853.073 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 1,749,191.789 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | -0.160 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | -0.100 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | -0.350 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 4 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 5 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Position: OVID demonstrates a stable balance sheet with healthy cash and cash equivalents, as reflected in the Balance Sheet data. A strong current ratio (currentRatioTTM) and quick ratio (quickRatioTTM) indicate good liquidity to cover short-term obligations, providing a buffer for operational needs or strategic investments.
- Positive Revenue Trends: Income Statement data shows consistent revenue growth over recent periods, supported by segment-specific contributions (Revenue Product Segments). This growth aligns with industry trends (Industry and Sector data), suggesting OVID is maintaining competitive positioning within its sector.
- Operational Efficiency: Key Metrics such as gross profit margin (grossProfitMarginTTM) and return on invested capital (roicTTM) indicate effective cost management and capital utilization, positioning OVID favorably against industry averages (industry_avg_priceToEarningsRatioTTM).
- Strong Management Insights: Earnings Call Transcript highlights from the latest quarter reflect management’s clear focus on achieving operational targets, with results often meeting or exceeding expectations, providing investor confidence in strategic execution.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates OVID intrinsic value between $23.74 – $35.29 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about OVID valuation
Is Ovid Therapeutics Inc. (OVID) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Ovid Therapeutics Inc. (OVID) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is OVID a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OVID trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is OVID’s P/E ratio?
You can see OVID’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for OVID?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is OVID a good long-term investment?
Whether OVID fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
Trading Metrics:
| Open: | 2.25 | Previous Close: | 2.26 | |
| Day Low: | 2.11 | Day High: | 2.25 | |
| Year Low: | 1.18 | Year High: | 3.11 | |
| Price Avg 50: | 2.63 | Price Avg 200: | 2.33 | |
| Volume: | 1.324M | Average Volume: | 2.118M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
